KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Gross Margin (2016 - 2025)

West Pharmaceutical Services' Gross Margin history spans 17 years, with the latest figure at 37.75% for Q4 2025.

  • For Q4 2025, Gross Margin rose 121.0% year-over-year to 37.75%; the TTM value through Dec 2025 reached 35.91%, up 140.0%, while the annual FY2025 figure was 35.91%, 140.0% up from the prior year.
  • Gross Margin for Q4 2025 was 37.75% at West Pharmaceutical Services, up from 36.58% in the prior quarter.
  • Across five years, Gross Margin topped out at 43.55% in Q2 2021 and bottomed at 32.76% in Q2 2024.
  • The 5-year median for Gross Margin is 37.93% (2023), against an average of 37.87%.
  • The largest annual shift saw Gross Margin soared 656bps in 2021 before it tumbled -590bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 41.13% in 2021, then fell by -10bps to 36.98% in 2022, then increased by 3bps to 38.01% in 2023, then fell by -4bps to 36.54% in 2024, then rose by 3bps to 37.75% in 2025.
  • Per Business Quant, the three most recent readings for WST's Gross Margin are 37.75% (Q4 2025), 36.58% (Q3 2025), and 35.73% (Q2 2025).